CGEM
Cullinan Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.84 EPS
Last earnings -1.8% on 2026-05-07
$17.75
▲ +2.60%$17.75▲ +113.34%
over 1Y
L $5.75EODHDH $17.75
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+2.6%
1W+31.0%
1M+14.8%
3M+30.1%
YTD+75.4%
1Y+113.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.10x); but revenue fell -100.0% YoY.
Cullinan Therapeutics, Inc. shows $0.00 in FY2022 revenue (-100.0% YoY), and -53.8% ROE.
Sources: SEC EDGAR (CIK 0001789972, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 9:56:19 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.